# A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata

> **NCT03354637** · PHASE2 · TERMINATED · sponsor: **Aclaris Therapeutics, Inc.** · enrollment: 129 (actual)

## Conditions studied

- Alopecia Areata

## Interventions

- **DRUG:** ATI-50002 high dose
- **DRUG:** ATI-50002 low dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03354637
- **Lead sponsor:** Aclaris Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-29
- **Primary completion:** 2019-04-18
- **Final completion:** 2019-09-10
- **Target enrollment:** 129 (ACTUAL)
- **Why stopped:** The double-blind primary endpoint was not met. Open Label Extension period halted as a result.
- **Last updated:** 2020-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03354637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03354637, "A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03354637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*